Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05205850 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Start date: March 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。

NCT ID: NCT05205421 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer

Start date: January 18, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.

NCT ID: NCT05205408 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, dose escalation, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) When Administered Via Intratumoral Injection in patients with advanced solid tumors. The primary purpose of this study is to evaluate the safety and tolerability, the secondary purpose is to evaluate the antitumor activity, immunoreactivity, immunogenicity, pharmacokinetics and virus shedding of RT-01.

NCT ID: NCT05204862 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Start date: December 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity of TU2218 at RP2D.

NCT ID: NCT05202561 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors

Start date: March 10, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, clinical pharmacology study to evaluate the safety of RNA tumor vaccine injection alone/in combination with PD-1 inhibitor in the treatment of advanced solid tumors with KRAS mutation. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, pharmacokinetics and of RNA tumor vaccine.

NCT ID: NCT05199753 Recruiting - Clinical trials for Advanced Solid Tumor

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Start date: March 16, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.

NCT ID: NCT05188664 Terminated - Clinical trials for Advanced Solid Tumor

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: May 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

NCT ID: NCT05183243 Recruiting - Colorectal Cancer Clinical Trials

Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors

Start date: February 20, 2022
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.

NCT ID: NCT05178888 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.

NCT ID: NCT05173805 Enrolling by invitation - Clinical trials for Advanced Solid Tumor

Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

Start date: January 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-15293 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.